binance futures specifications,BeiGene recently announced that the BTK inhibitor zanubrutinib has been approved for marketing by the US Food and Drug Administration ( FDA ) for the treatment of adult patients with mantle cell lymphoma who have previously received at least one therapy. At this point, "the drug has become the first anti-cancer new drug that was independently developed by a Chinese domestic company and approved by the FDA , which has achieved a 'zero breakthrough' for Chinese original new drugs to go to sea." Dr. Wu Xiaobin, General Manager and President of BeiGene China Say.
